In short
Taminadenant, also known as NIR178, is an investigational drug being studied in clinical trials for patients with various types of advanced cancer. This article explores the ongoing research into Taminadenant's safety and tolerability, as well as its potential benefits for cancer patients who have participated in previous Novartis-sponsored studies.
At a glance
- Drug Name
- Taminadenant (NIR178)
- Study Type
- Open-label, multi-center rollover protocol
- Target Population
- Patients with different types of advanced cancer
- Main Objective
- Collect safety and tolerability data for Taminadenant
- Secondary Objective
- Provide continued access to study treatment
- Administration
- Oral use, hard capsules
- Maximum Daily Dose
- 480 mg
- Maximum Treatment Period
- 533 days
- Primary Endpoint
- Frequency and nature of adverse events and serious adverse events
- Secondary Endpoint
- Number of subjects receiving treatment and duration of exposure
What is TAMINADENANT?
TAMINADENANT is an investigational drug being developed by Novartis Pharma AG for the treatment of various types of advanced cancer. It is also known by its product code NIR178. This medication is currently being studied in clinical trials to evaluate its safety and effectiveness in cancer patients.
Medical Conditions Treated
TAMINADENANT is being investigated for the treatment of different types of advanced cancer. Advanced cancer refers to cancer that has spread from its original site to other parts of the body or has grown significantly and is difficult to treat with standard therapies. The specific types of cancer being targeted in the clinical trials are not specified in the provided information.
Drug Administration
TAMINADENANT is administered as a hard capsule for oral use. This means patients can take the medication by mouth, which is generally more convenient than other forms of cancer treatments like intravenous infusions. The maximum daily dose being studied is 480 mg. The treatment period can last up to 533 days (approximately 1.5 years), although this may vary depending on the patient's response and the specific clinical trial protocol.
Clinical Trials and Safety
TAMINADENANT is currently being evaluated in clinical trials to assess its safety and effectiveness. The primary focus of these trials is to collect data on the safety and tolerability of the drug when used alone or in combination with other treatments. Researchers are particularly interested in:
- The frequency and nature of adverse events (AEs) and serious adverse events (SAEs)
- The number of patients requiring dose interruptions or reductions
- The duration of exposure to the drug
This information helps researchers and doctors understand how well patients can tolerate the medication and what side effects they might experience.
Eligibility for Treatment
To be eligible for treatment with TAMINADENANT in these clinical trials, patients typically need to meet certain criteria:
- They must be currently enrolled in a pre-defined Novartis-sponsored study involving TAMINADENANT
- They should be receiving clinical benefit from the treatment, as determined by their doctor
- They must have demonstrated compliance with the previous study's requirements
- They must be willing and able to comply with scheduled visits and treatment plans
It's important to note that eligibility criteria may vary between different clinical trials, and a healthcare professional should be consulted for specific information.
Potential Benefits
While the full benefits of TAMINADENANT are still being studied, the ongoing clinical trials suggest that it may offer potential advantages for patients with advanced cancer. Some possible benefits include:
- A new treatment option for patients who may have limited alternatives
- Oral administration, which can be more convenient than other cancer treatments
- Potential for use alone or in combination with other cancer therapies
- Continued access to the drug for patients who have shown benefit in previous trials
It's important to remember that as an investigational drug, the full efficacy and safety profile of TAMINADENANT is still being determined through clinical trials. Patients should discuss the potential risks and benefits with their healthcare provider to make informed decisions about their treatment options.